Sentences with phrase «juno therapeutics»

Her representative clients include: T - Mobile USA, ClearOne, TiVo, BlackBerry, Columbia University, Juno Therapeutics, Core Wireless, and The Los Angeles Dodgers.

While at Fred Hutch, he led the Center's spin - out efforts to help launch companies including Juno Therapeutics, Adaptive Biotechnologies, Presage Biosciences and Blaze Biosciences.

«Be critical,» said Dr. Philip Greenberg of the University of Washington, who's also scientific cofounder of Juno Therapeutics, one of the companies leading the search for immune - based treatments for cancer.

The NEJM letter was co-authored by Brianne McGree, NP, Sarah Noyes, Sean Plummer, Curtis Wong, Yi - Bin Chen, MD, and Isabel C. Arrillaga - Romany, MD, PhD, MGH Cancer Center; Edwin Palmer, MD, MGH Radiology; Judith Ferry, MD, MGH Pathology, and Tina Albertson, MD, PhD, Juno Therapeutics.

Kite is similarly ambitious with its work in CAR - T, and so too is Juno Therapeutics.

He is the Vice President, Process and Analytical Development at Juno Therapeutics in Seattle, Washington.

(Trials of another CAR - T therapy, by Juno Therapeutics, were halted in 2016 after five patients died from brain swelling.)

This clinical trial sponsored by Juno Therapeutics is testing JCAR017, which targets the CD19 protein expressed on most B - cell leukemias and lymphomas.

Then immunotherapy firm Juno Therapeutics shook hands with gene - editing start - up Editas to create anticancer immune cell therapies; Vertex Pharmaceuticals and Crispr Therapeutics, another start - up, inked an agreement that could be valued at $ 2.6 billion; while Regeneron Pharmaceuticals formed a patent licence agreement with ERS Genomics, which holds the rights to the foundational Crispr intellectual property from Emmanuelle Charpentier, one of the Crispr pioneers.

Furthermore, Celgene is generating free cash flow at a rate of over $ 1 billion per quarter, giving it plenty of options to acquire new drugs, such as with the deal it announced earlier this month to buy Impact Biomedicines and its potential blockbuster drug for a rare form of blood cancer, and its latest announced buyout of CAR - T developer Juno Therapeutics.

Immunotherapy has been emerging from the backdrop of oncology research for years most notably from smaller companies such as Dendreon, Kite Pharma and Juno Therapeutics as leaders in the space.

So far the company has done jack shit for business, aside from drum up a deal with Juno Therapeutics which gave them $ 25 million shekels for the boffins to run around and figure some shit out.

Juno Therapeutics is seeking to change the protocol for the Phase II ROCKET clinical trial of its acute lymphoblastic leukemia candidate JCAR015, which the FDA has placed on clinical hold following the deaths of three patients, two of them last week.

For the second time in 5 months, Juno Therapeutics has put a clinical hold on a Phase II trial of JCAR015 in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia due to patient deaths.

Juno Therapeutics will resume its Phase II ROCKET clinical trial of its acute lymphoblastic leukemia candidate JCAR015 following the FDA's lifting of a partial clinical hold imposed last week following the deaths of three patients.

Another speculative immunotherapy stock is Juno Therapeutics (JUNO).

Celgene and bluebird bio report a stunning success in multiple myeloma, Juno Therapeutics takes it on the chin despite positive data, and Spark Therapeutics suffers in its showdown with BioMarin in hemophilia.

Rumors are swirling that Celgene may pay billions to buy Juno Therapeutics lock - stock - and - barrel.

Kite is one of the leading players in the emerging field of CAR T, and is competing with rivals Novartis AG, Juno Therapeutics Inc and Bluebird Bio Inc in a race to get the first approved therapy.

Several other venture - backed companies such as Juno Therapeutics are developing other promising compounds in this space.

Juno Therapeutics» cancer study has now been allowed to resume a week after its clinical trials were suspended by the FDA.

Fellow pharmaceutical company Celgene Corp. agreed to acquire Juno Therapeutics Inc. for about $ 9 billion.

The company on Monday agreed to acquire Juno Therapeutics for about $ 9 billion.

Kite Pharma, Juno Therapeutics, and Bluebird Bio are among a growing group of biotech companies working with CAR - T.

But while the technology itself is undeniably exciting, some companies, like Juno Therapeutics, have been struggling with the reality of dangerous side effects including cytokine release syndrome and brain swelling during trials.

This month has seen a spike in multibillion - dollar deals in biotech, with U.S. - based Celgene paying $ 9 billion for cancer specialist Juno Therapeutics, and several experts predicting a bumper year for M&A.

Celgene agrees to buy rest of Juno Therapeutics it doesn't already own for about $ 9 billion in cash to gain access to Juno's pipeline of CAR - T cancer drugs.

Shares of Juno Therapeutics were up 27 percent on the news, to just below the offering price.

Jefferies» Michael Yee discusses the big deals in biotech, like Celgene's acquisition of Juno Therapeutics, and what means for the rest of the sector.

CNBC's Meg Tirrell reports on two major deals in the biotech space: Sanofi buying Bioverativ and Celgene buying Juno Therapeutics.

Competition: Most of the venture capital for synthetic biology applications has gone to companies like Seattle - based Juno Therapeutics, which does genetic engineering to help patients fight disease.

CAR - T treatments, including competing products from Novartis rivals Kite Pharma and Juno Therapeutics, come with the risk of potentially deadly side effects such as cytokine - release syndrome (CRS), in which a glut of T - cell - assisting cytokines can cause high fever, low blood pressure, and problems with lung oxygenation.

The patient died of cerebral edema (brain swelling)-- a deadly adverse event that also afflicted Kite competitor Juno Therapeutics» rival drug in the space, which it was then forced to abandon.

Juno Therapeutics.

Cancer drug company Juno Therapeutics, which took in $ 145 million from Amazon's Jeff Bezos and other investors in 2014 is but one example.